Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TTP889 · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| TTP889 | DRUG | - |
Inclusion Criteria: * Must have undergone reparative surgery within 72 hours after unilateral hip fracture, defined as fracture of the upper third of either femur * Must have started standard prophylactic treatment for VTE with low molecular weight heparin (LMWH) or heparin before surgery or within...
TTP889 is an investigational small molecule being developed for the prevention of venous thromboembolism, a condition involving blood clots in the veins. It was studied in patients with hip fractures who are at risk for embolism and thrombosis. The drug is currently in Phase 2 clinical development and is not approved by regulatory authorities.
TTP889 targets Factor IX, a protein involved in the blood clotting cascade. By inhibiting Factor IX, the drug is designed to prevent the formation of blood clots that can lead to venous thromboembolism. This mechanism was evaluated in the FIXIT trial for thrombosis prevention in patients with hip fractures.
TTP889 is being developed by vTv Therapeutics Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol VTVT. The company is conducting clinical research on this investigational small molecule for the prevention of venous thromboembolism in patients at risk due to hip fractures.
TTP889 is in Phase 2 clinical development. It has completed one Phase 2 trial, the FIXIT trial, which enrolled 300 participants. The drug is investigational and has not been approved by the FDA or other regulatory agencies. No active trials are currently listed for this asset.
TTP889 has one completed clinical trial, the Factor IX Inhibition in Thrombosis Prevention (FIXIT) trial, registered as NCT00119457. This Phase 2 study enrolled 300 participants with venous thromboembolism, embolism, thrombosis, and hip fractures across Czechia, Denmark, Norway, and Sweden. The trial was randomized and double-blind.
TTP889 is the sole name provided for this investigational drug. It is not known by any alternative names in the available information. The drug is a small molecule developed by vTv Therapeutics Inc. for the prevention of venous thromboembolism, and it is currently in Phase 2 clinical development.